|
|
||||||||


* Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom; and
Vaccine Evaluation Department, Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
Naturally acquired protective immunity against Neisseria meningitidis is thought to partially explain the disparity between the high levels of carriage in the human nasopharynx and the rare incidence of disease. To investigate this immunity to Neisseria meningitidis at the mucosal level, in vitro cellular responses to outer membrane vesicle preparations derived from this pathogen were examined using mononuclear cells from the palatine tonsils of adults and children. Characterization of these responses was achieved by depletion of CD45RA+, CD45RO+, and CD19+ populations and outer membrane vesicles derived from isogenic mutants expressing different serosubtypes of the major outer membrane protein, porin A (PorA), no PorA and membrane preparations from a mutant with no LPS (LpxA-). The magnitude of cellular proliferative responses against the outer membrane vesicles were strongly associated with age and were largely T cell mediated, involving both CD45RO+ and CD45RA+ T cell phenotypes. Responses were not dependent on LPS but consisted of both PorA cross-specific and non-PorA-dependent responses. Cellular immunity against Neisseria meningitidis was found to be frequently associated with systemic IgG Abs but was not associated with serum bactericidal Abs. For the first time our results demonstrate an age-associated acquisition of mucosal T effector/memory cell responses to Neisseria meningitidis. This mucosal cellular immunity can be present in the absence of serum bactericidal Abs, a classical marker of protective immunity.
This article has been cited by other articles:
![]() |
C. Trotter, J. Findlow, P. Balmer, A. Holland, R. Barchha, N. Hamer, N. Andrews, E. Miller, and R. Borrow Seroprevalence of Bactericidal and Anti-Outer Membrane Vesicle Antibodies to Neisseria meningitidis Group B in England Clin. Vaccine Immunol., July 1, 2007; 14(7): 863 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Lear, E Eren, J Findlow, R Borrow, D Webster, and S Jolles Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin. J. Clin. Pathol., November 1, 2006; 59(11): 1191 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Findlow, S. Taylor, A. Aase, R. Horton, R. Heyderman, J. Southern, N. Andrews, R. Barchha, E. Harrison, A. Lowe, et al. Comparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvac. Infect. Immun., August 1, 2006; 74(8): 4557 - 4565. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Robinson, K. G. Wooldridge, D. B. Wells, A. Hasan, I. Todd, A. Robins, R. James, and D. A. A. Ala'Aldeen T-Cell-Stimulating Protein A Elicits Immune Responses during Meningococcal Carriage and Human Disease Infect. Immun., August 1, 2005; 73(8): 4684 - 4693. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Meiring, B. Kuipers, J. A. M. van Gaans-van den Brink, M. C. M. Poelen, H. Timmermans, G. Baart, H. Brugghe, J. van Schie, C. J. P. Boog, A. P. J. M. de Jong, et al. Mass Tag-Assisted Identification of Naturally Processed HLA Class II-Presented Meningococcal Peptides Recognized by CD4+ T Lymphocytes J. Immunol., May 1, 2005; 174(9): 5636 - 5643. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |